News | August 09, 2010

Researchers Say New Protocol May Lower CT Dose by Nearly 50 Percent


August 9, 2010 - Researchers at Mayo Clinic are working to reduce radiation dosages used to acquire perfusion and other CT images.

The As Low As Reasonably Achievable, or ALARA, principle has always guided Mayo Clinic’s approach to the dosages of radiation used to acquire CT images. Dr. McCollough’s team has been experimenting with a newly created image-processing algorithm that produces high-quality perfusion CTs with up to 20 times less the radiation used under existing protocols.

“We believe in the clinical value of perfusion CT, and though there is no documented risk of injury at the currently prescribed radiation levels, we are trying to lower the dose for the benefit of patients,” said Cynthia McCollough, diagnostic radiologist, Mayo Clinic.

Depending on the diagnostic application, a perfusion CT exam takes about 30 seconds to scan the tissue multiple times after iodine has been injected. This technique detects changes in blood volume and flow that reveal injuries to vessels or a tumor’s response to treatment. Information from each consecutive scan is then digitally cross-referenced with other images taken during the exam to improve image quality and reduce distortions.

McCollough, Ph.D., and her group of researchers presented their findings related to CT dose reduction at the 52nd Annual Meeting of the American Association of Physicists in Medicine on July 20 in Philadelphia. The presentation was entitled “20-Fold Dose Reduction Using a Gradient Adaptive Bilateral Filter: Demonstration Using in Vivo Animal Perfusion CT.”

Thus far, the new perfusion CT algorithms have proved effective in animal models, and Dr. McCollough’s team has begun looking at ways to introduce the methodologies into clinical practice.

“When we use very low doses of radiation to acquire a CT, image graininess can significantly decrease the value of the exam,” says the study’s first author, Juan Carlos Ramirez Giraldo, Mayo Clinic. “With this new algorithm, we are able to maintain the image quality by cross-referencing it with other images collected during the exam.”

In related efforts, a team of radiologists and physicists have recently implemented a new routine head CT protocol that cuts radiation dose by nearly 50 percent. While the American College of Radiology allows its accredited facilities to use head CT doses up to approximately 75 mGy, Mayo Clinic’s newly introduced patient protocol uses a dose of only 38 mGy. This dose reduction is particularly significant as head CT exams are one of the most commonly performed CT procedures.

When asked how the new head CT protocol is changing clinical practice, neuroradiologist David DeLone, M.D., Mayo Clinic, says, “patients aren’t aware that anything has changed, and as radiologists looking at a study, we don’t know anything has changed. Yet, we are obtaining high-quality images, more consistently and in shorter times, while exposing patients to about half of the radiation dose. It’s a win-win for everyone.”

For more information: www.mayo.edu


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now